Bendamustine – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 67 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Bendamustine - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma. Bendamustine therapy is associated with minor transient serum enzyme elevations during treatment and with rare instances...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma. Bendamustine therapy is associated with minor transient serum enzyme elevations during treatment and with rare instances of clinically apparent liver injury, with jaundice generally arising as a part of a generalized hypersensitivity syndrome. Bendamustine also has...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma. Bendamustine therapy is associated with minor transient serum enzyme elevations during treatment and with rare instances of clinically apparent liver injury, with jaundice generally arising as a part of a generalized hypersensitivity syndrome. Bendamustine also has potent immunosuppressive activity and can cause reactivation of chronic hepatitis B which can be severe and even fatal.

Bendamustine is a bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA, and protein synthesis inhibition, and eventually the induction of apoptosis.

Bendamustine Hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.

Mechanism of Action

Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Multiple myeloma is a fatal hematological disease caused by the malignant transformation of plasma cells. Bendamustine has been proven to be a potent alternative to melphalan in phase 3 studies, yet its molecular mode of action is still poorly understood. The four-myeloma cell lines NCI-H929, OPM-2, RPMI-8226, and U266 were cultured in vitro. Apoptosis was measured by flow cytometry after annexin V FITC and propidium iodide staining. The cell cycle distribution of cells was determined by DNA staining with propidium iodide. Intracellular levels of (phosphorylated) proteins were determined by western blot. /It was shown/ that bendamustine induces apoptosis with an IC50 of 35-65 mg/ml and with cleavage of caspase 3. Incubation with 10-30 mg/ml results in G2 cell cycle arrest in all four-cell lines. The primary DNA-damage signaling kinases ATM and Chk2, but not ATR and Chk1, are activated. The Chk2 substrate Cdc25A phosphatase is degraded and Cdc2 is inhibited by inhibitory phosphorylation of Tyr15 accompanied by increased cyclin B levels. Additionally, p53 activation occurs as phosphorylation of Ser15, the phosphorylation site for ATM. p53 promotes Cdc2 inhibition by upregulation of p21. Targeting of p38 MAPK by the selective inhibitor SB202190 significantly increases bendamustine-induced apoptosis. Additionally, SB202190 completely abrogates G2 cell cycle arrest. Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53-mediated apoptosis. Inhibition of p38 MAPK augments apoptosis and abrogates G2 arrest and can be considered a new therapeutic strategy in combination with bendamustine.

Indications

  • Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Ho
  • Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma.
  • B-cellnon-Hodgkin lymphoma (NHL) is indolent (slow-growing) and got worse during or within 6 months after treatment with rituximab.
  • Chronic lymphocytic leukemia (CLL).
  • Bendamustine hydrochloride is used for the treatment of chronic lymphocytic leukemia (CLL) and is designated an orphan drug by the US Food and Drug Administration (FDA) for use in this condition.
  • Bendamustine administered as monotherapy is active in rituximab-refractory indolent non-Hodgkin’s lymphoma, predominantly in patients with nontransformed or with sensitive disease characteristics. Therefore, bendamustine may be considered a reasonable choice for rituximab-refractory, indolent non-Hodgkin’s lymphoma; bendamustine may also may be considered an alternative in patients who are not candidates for radioimmunotherapy due to either patient selection (i.e., a clinical contraindication) or accessibility issues.
  • Chronic Lymphocytic Leukemia (CLL)
  • Follicular Non-Hodgkin’s Lymphoma Refractory
  • Refractory Hodgkin Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Waldenström’s Macroglobulinemia (WM)
  • Recurrent multiple myeloma
  • Refractory indolent B cell non-hodgkin lymphoma

Use in Cancer

Bendamustine hydrochloride is approved to treat:

Bendamustine hydrochloride is also being studied in the treatment of other types of cancer.

Contraindications

  • are allergic to bendamustine hydrochloride or any ingredients of this medication, including mannitol
  • a bad infection
  • malignant melanoma, a type of skin cancer
  • dehydration
  • high levels of potassium in the blood
  • anemia
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • tobacco smoking
  • progressive multifocal leukoencephalopathy, a type of brain infection

Dosage

Strengths: 25 mg/mL; 25 mg; 100 mg; 90 mg/mL

Chronic Lymphocytic Leukemia

  • 100 mg/m2 IV on Days 1 and 2 of a 28-day cycle
  • Duration of Therapy: Up to 6 cycles
  • Administer this drug via IV infusion over 30 minutes; consult the manufacturer’s product information for a specific IV infusion time period.
  • Efficacy of this drug relative to first-line therapies other than chlorambucil has not been established.
  • This drug is available in two formulations, a solution and a lyophilized powder; do not mix or combine the two formulations.

Non-Hodgkin’s Lymphoma

  • 120 mg/m2 IV on Days 1 and 2 of a 21-day cycle
  • Duration of Therapy: Up to 8 cycles
  • Administer this drug via IV infusion over 60 minutes; consult the manufacturer product information for specific IV infusion time period.
  • This drug is available in two formulations, a solution and a lyophilized powder; do not mix or combine the two formulations.

Renal Dose Adjustments

  • Mild to Moderate Renal Dysfunction: Use with caution.
  • Severe Renal Dysfunction (CrCl less than 30 mL/min): Not recommended.

Liver Dose Adjustments

  • Mild Liver Dysfunction: Use with caution.
  • Moderate Liver Dysfunction (AST or ALT 2.5 to 10 x Upper Limit of Normal and Total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">Bilirubin 1.5 to 3 x ULN): Not recommended.
  • Severe Liver Dysfunction (Total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">Bilirubin greater than 3 x ULN): Not recommended.

Dose Adjustments

Chronic Lymphocytic Leukemia (CLL) or Non-Hodgkin Lymphoma (NHL):

  • Grade 4 Hematologic Toxicity or Clinically Significant Grade 2 or Greater Non-Hematologic Toxicity: Delay treatment; reinitiate therapy at a physician’s discretion once non-hematologic toxicity has recovered to Grade 1 or less and/or absolute bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count (ANC) 1 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater; dose reduction may be warranted.

CLL:
Grade 3 or Greater Hematologic Toxicity: Reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle.

  • If Grade 3 or greater toxicity recurs, reduce dose to 25 mg/m2 on Days 1 and 2 of each cycle.
  • Dose re-escalation in subsequent cycles may be considered per physician discretion.

Clinically Significant Grade 3 or Greater Non-Hematologic Toxicity: Reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle.

  • Dose re-escalation in subsequent cycles may be considered per physician discretion.

NHL:
Grade 4 Hematologic Toxicity or Grade 3 or Greater Non-Hematologic Toxicity: Reduce dose to 90 mg/m2 on Days 1 and 2 of each cycle.

  • If Grade 4 hematologic or Grade 3 or greater non-hematologic toxicity recurs, reduce dose to 60 mg/m2 on Days 1 and 2 of each cycle.

Side Effects

The Most Common

  • nausea
  • vomiting
  • diarrhea
  • heartburn
  • constipation
  • stomach pain or swelling
  • sores or white patches in the mouth
  • dry mouth
  • bad taste in the mouth or difficulty tasting food
  • loss of appetite
  • weight loss
  • headache
  • anxiety
  • depression
  • difficulty falling asleep or staying asleep
  • back, bone, joint, arm or leg pain
  • dry skin
  • sweating
  • night sweats

More common

  • pain in the place where the medication was injected
  • hives
  • rash
  • itching
  • blistering or peeling skin
  • difficulty breathing or swallowing
  • swelling of the eyes, face, lips, tongue, arms, hands, feet, ankles, or lower legs
  • shortness of breath
  • chest pain
  • fast heartbeat
  • excessive tiredness or weakness
  • pale skin
  • fever, chills, cough, or other signs of infection
  • nausea; vomiting; unusual bleeding or bruising; yellowing of the skin or eyes, dark urine, or light colored stool; tenderness on the right upper side of the stomach

Rare

  • dehydration (thirst, dizziness, dry mouth, less urine output)
  • difficulty breathing
  • fever (over 38°C, or as instructed by your physician or clinic)
  • lumps or discoloured patches on the skin
  • signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
  • signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
  • signs of increased uric acid in the body (gout; e.g., joint pain, swelling and warmth of joints)
  • signs of heart problems (e.g., fast, irregular heartbeat or pulse, chest pain, sudden weight gain, difficulty breathing, leg swelling)
  • signs of kidney problems (e.g., increased urination at night, decreased urine production, blood in the urine, change of urine colour)
  • signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
  • skin growths or changes to existing skin growths or sores
  • skin rash
  • symptoms of extravasation (leakage of drug from the veins; redness, pain, swelling or infection at the site of infusion)
  • symptoms of an infection such as fever, chills, or painful and difficult urination
  • symptoms of a new cancer (e.g., weight loss, fatigue, night sweats, loss of appetite, coughing up blood, persistent cough, fever, frequent infections, bone pain)
  • symptoms of irregular heartbeat (e.g., chest pain, dizziness, rapid, pounding heartbeat, shortness of breath)
  • symptoms of low potassium levels in the blood (e.g., weakness, fatigue, muscle cramps, irregular heartbeat)
  • symptoms of a lung infection (e.g., shortness of breath, cough, chest pain)
  • symptoms of scarring of the lung (e.g., shortness of breath, fatigue, fever, infection)
  • symptoms of severely increased blood pressure (e.g., chest pain, blurred vision, dizziness, excessive tiredness, headache, stronger or faster heart beat)

Seek immediate medical attention if any of the following occur:

  • signs of bleeding in the stomach (e.g., bloody, black, or tarry stools, spitting up of blood, vomiting blood or material that looks like coffee grounds)
  • signs of a heart attack (e.g., chest pain or pressure, pain extending through shoulder and arm, nausea and vomiting, sweating)
  • symptoms of a serious allergic reaction, such as hives, difficulty breathing, or swelling of the eyelids, throat, and mouth
  • signs of a severe skin reaction such as blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort
  • symptoms of progressive multifocal leukoencephalopathy (PML) (e.g., memory loss, trouble thinking, difficulty walking, loss of sight)
  • symptoms of tumor lysis syndrome (e.g., producing less urine, cloudy urine, kidney problems, muscle spasms, nausea, shortness of breath)

Bendamustine therapy is associated with minor transient serum enzyme elevations during treatment and to rare instances of clinically apparent liver injury, with jaundice generally arising as a part of a generalized hypersensitivity syndrome. Bendamustine also has potent immunosuppressive activity and can cause reactivation of chronic hepatitis B that can be severe and even fatal.

Drug Interaction

Pregnancy and Lactation

Pregnancy category D

Pregnancy

There is a possibility of birth defects if either the man or woman is taking bendamustine at the time of conception, or if it is taken during pregnancy. Use effective birth control starting 2 weeks before receiving this medication and for at least 4 weeks after receiving your last dose. If you become pregnant while taking this medication, contact your doctor immediately.

Lactation

No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as bendamustine.[1] Based on the half-life of the drug and its metabolites, the drug should be eliminated from the milk by 24 to 48 hours after the last dose. The manufacturer recommends that breastfeeding be discontinued during bendamustine therapy and for at least 1 week after the last dose.

How should this medicine be used?

For chronic lymphocytic leukemia, the usual adult dose is 100 mg per square metre of body surface area. It is given intravenously (directly into a vein) over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.

For non-Hodgkin’s lymphoma, the usual dose is 120 mg per square metre of body surface area. It is given intravenously (directly into a vein) over 60 minutes of Days 1 and 2 of a 21-day cycle, up to 8 cycles.

Bendamustine comes as a solution (liquid) or as a powder to be mixed with liquid and injected intravenously (into a vein) over 10 minutes or infused intravenously over 30 or 60 minutes by a doctor or nurse in a medical office or hospital outpatient clinic. When bendamustine injection is used to treat CLL, it is usually injected once a day for 2 days, followed by 26 days when the medication is not given. This treatment period is called a cycle, and the cycle may be repeated every 28 days for as long as 6 cycles. When bendamustine injection is used to treat NHL, it is usually injected once a day for 2 days, followed by 19 days when the medication is not given. This treatment cycle may be repeated every 21 days for up to 8 cycles.

Your doctor may need to delay your treatment and adjust your dose if you experience certain side effects. Your doctor may also give you other medication(s) to prevent or treat certain side effects. Be sure to tell your doctor how you are feeling during your treatment with bendamustine injection.

What special precautions should I follow?

Before receiving bendamustine injection,

  • tell your doctor and pharmacist if you are allergic to bendamustine, any other medications, or any of the ingredients in bendamustine injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: ciprofloxacin (Cipro), fluvoxamine (Luvox, and omeprazole (Prilosec). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may interact with bendamustine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have or have ever had cytomegalovirus infection (CMV; a viral infection that may cause symptoms in patients with weak immune systems), hepatitis B virus infection (HBV; an ongoing liver infection), tuberculosis (TB; a serious infection that affects the lungs and sometimes other parts of the body), herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past), or kidney or liver disease.
  • tell your doctor if you are pregnant or plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are receiving bendamustine injection. You should use birth control to prevent pregnancy in yourself or your partner during your treatment with bendamustine injection and for 3 months afterwards. Talk to your doctor about birth control methods that will work for you. If you or your partner becomes pregnant while receiving bendamustine injection, call your doctor. Bendamustine injection can harm the fetus.
  • tell your doctor if you are breast-feeding. You should not breastfeed during your treatment with bendamustine.
  • you should know that bendamustine injection may make you tired. Do not drive a car or operate machinery until you know how this medication affects you.
  • tell your doctor if you use tobacco products. Smoking may decrease the effectiveness of this medication.

Before you begin taking a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should take this medication.

Low red blood cell count: This medication can reduce the number of red blood cells in the blood. Red blood cells help provide oxygen to different tissues in the body. Tell your doctor of any signs that your red blood cell count is low. Such symptoms may include feeling unusually tired, decreased levels of alertness, loss of appetite, paler-than-normal skin, trouble breathing, or rapid heartbeat.

Blood clotting: This medication can reduce the number of platelet cells in the blood. Platelets help the blood to clot, and a shortage could make you bleed more easily. Tell your doctor of any signs that your blood is not clotting as quickly. Such symptoms may include black and tarry stools, blood in the urine, easy bruising, or cuts that won’t stop bleeding.

Blood pressure: Bendamustine can cause increased blood pressure. If you have high blood pressure or are taking medications to control blood pressure, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

Extravasation: When bendamustine leaks into tissue surrounding a vein, symptoms such as redness, swelling, and pain can occur around the place of injection. This is called extravasation. If you develop symptoms of extravasation, tell your doctor or nurse immediately.

Heart problems: Bendamustine can cause heart problems such as heart failure, chest pain, heart attack, and abnormal heart rhythms. If you have heart problems, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

Infection: As well as killing cancer cells, this medication can reduce the number of cells that fight infection in the body (white blood cells). Avoid contact with people who have contagious infections and tell your doctor if you begin to notice signs of an infection such as fever or chills.

Infertility: Men treated with bendamustine may develop infertility that may last for several years after stopping treatment. Talk to your doctor about infertility management options.

Infusion reaction: When bendamustine is given, you may experience an infusion reaction (fever, chills, skin rash or itchiness). If you experience an infusion reaction, your doctor may prescribe medications (e.g., antihistamines, acetaminophen, corticosteroids) to be given before future infusions to prevent another reaction.

Kidney problems: If you have kidney problems, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

Liver problems: Bendamustine can affect your liver function. If you have severe liver problems, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

If you experience symptoms of liver problems such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin, contact your doctor immediately.

Progressive multifocal leukoencephalopathy (PML): There have been reports of PML after using bendamustine. PML is a rare disorder that causes nerve damage in the brain. If you experience memory loss, vision changes, trouble thinking, personality changes or difficulty walking, contact your doctor immediately.

Secondary cancer: This medication can increase the risk of developing leukemia, lung cancer, or certain types of skin cancer. If you are concerned about this, talk to your doctor about the risks and benefits of using this medication.

Surgery: If you need surgery, tell your doctor or anesthetist that you are taking this medication.

Tumour lysis syndrome: Bendamustine, like many other cancer medications, causes many cancer cells to be suddenly killed when treatment is first started. This can overwhelm the body with waste products from the cells. As a result, the body may not be able to keep up with getting rid of all the waste. When this happens, you may have nausea, shortness of breath, cloudy urine, or joint pain. This is called tumour lysis syndrome. Your doctor may prescribe some medications to help your body get rid of the waste products. Make sure you understand how to use these medications and report any of these signs or symptoms to your doctor immediately.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Bendamustine – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown. Multiple myeloma is a fatal hematological disease caused by the malignant transformation of plasma cells. Bendamustine has been proven to be a potent alternative to melphalan in phase 3 studies, yet its molecular mode of action is still poorly understood. The four-myeloma cell lines NCI-H929, OPM-2, RPMI-8226, and U266 were cultured in vitro. Apoptosis was measured by flow cytometry after annexin V FITC and propidium iodide staining. The cell cycle distribution of cells was determined by DNA staining with propidium iodide. Intracellular levels of (phosphorylated) proteins were determined by western blot. /It was shown/ that bendamustine induces apoptosis with an IC50 of 35-65 mg/ml and with cleavage of caspase 3. Incubation with 10-30 mg/ml results in G2 cell cycle arrest in all four-cell lines. The primary DNA-damage signaling kinases ATM and Chk2, but not ATR and Chk1, are activated. The Chk2 substrate Cdc25A phosphatase is degraded and Cdc2 is inhibited by inhibitory phosphorylation of Tyr15 accompanied by increased cyclin B levels. Additionally, p53 activation occurs as phosphorylation of Ser15, the phosphorylation site for ATM. p53 promotes Cdc2 inhibition by upregulation of p21. Targeting of p38 MAPK by the selective inhibitor SB202190 significantly increases bendamustine-induced apoptosis. Additionally, SB202190 completely abrogates G2 cell cycle arrest. Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53-mediated apoptosis. Inhibition of p38 MAPK augments apoptosis and abrogates G2 arrest and can be considered a new therapeutic strategy in combination with bendamustine. Indications Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Ho Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma. B-cellnon-Hodgkin lymphoma (NHL) is indolent (slow-growing) and got worse during or within 6 months after treatment with rituximab. Chronic lymphocytic leukemia (CLL). Bendamustine hydrochloride is used for the treatment of chronic lymphocytic leukemia (CLL) and is designated an orphan drug by the US Food and Drug Administration (FDA) for use in this condition. Bendamustine administered as monotherapy is active in rituximab-refractory indolent non-Hodgkin's lymphoma, predominantly in patients with nontransformed or with sensitive disease characteristics. Therefore, bendamustine may be considered a reasonable choice for rituximab-refractory, indolent non-Hodgkin's lymphoma; bendamustine may also may be considered an alternative in patients who are not candidates for radioimmunotherapy due to either patient selection (i.e., a clinical contraindication) or accessibility issues. Chronic Lymphocytic Leukemia (CLL) Follicular Non-Hodgkin's Lymphoma Refractory Refractory Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Waldenström's Macroglobulinemia (WM) Recurrent multiple myeloma Refractory indolent B cell non-hodgkin lymphoma Use in Cancer Bendamustine hydrochloride is approved to treat: B-cell non-Hodgkin lymphoma (NHL) is indolent (slow-growing) and got worse during or within 6 months after treatment with rituximab. Chronic lymphocytic leukemia (CLL). Bendamustine hydrochloride is also being studied in the treatment of other types of cancer. Contraindications are allergic to bendamustine hydrochloride or any ingredients of this medication, including mannitol a bad infection malignant melanoma, a type of skin cancer dehydration high levels of potassium in the blood anemia decreased blood platelets low levels of a type of white blood cell called neutrophils abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding tobacco smoking progressive multifocal leukoencephalopathy, a type of brain infection Dosage Strengths: 25 mg/mL; 25 mg; 100 mg; 90 mg/mL Chronic Lymphocytic Leukemia 100 mg/m2 IV on Days 1 and 2 of a 28-day cycle Duration of Therapy: Up to 6 cycles Administer this drug via IV infusion over 30 minutes; consult the manufacturer's product information for a specific IV infusion time period. Efficacy of this drug relative to first-line therapies other than chlorambucil has not been established. This drug is available in two formulations, a solution and a lyophilized powder; do not mix or combine the two formulations. Non-Hodgkin's Lymphoma 120 mg/m2 IV on Days 1 and 2 of a 21-day cycle Duration of Therapy: Up to 8 cycles Administer this drug via IV infusion over 60 minutes; consult the manufacturer product information for specific IV infusion time period. This drug is available in two formulations, a solution and a lyophilized powder; do not mix or combine the two formulations. Renal Dose Adjustments Mild to Moderate Renal Dysfunction: Use with caution. Severe Renal Dysfunction (CrCl less than 30 mL/min): Not recommended. Liver Dose Adjustments Mild Liver Dysfunction: Use with caution. Moderate Liver Dysfunction (AST or ALT 2.5 to 10 x Upper Limit of Normal and Total Bilirubin 1.5 to 3 x ULN): Not recommended. Severe Liver Dysfunction (Total Bilirubin greater than 3 x ULN): Not recommended. Dose Adjustments Chronic Lymphocytic Leukemia (CLL) or Non-Hodgkin Lymphoma (NHL): Grade 4 Hematologic Toxicity or Clinically Significant Grade 2 or Greater Non-Hematologic Toxicity: Delay treatment; reinitiate therapy at a physician's discretion once non-hematologic toxicity has recovered to Grade 1 or less and/or absolute neutrophil count (ANC) 1 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater; dose reduction may be warranted. CLL: Grade 3 or Greater Hematologic Toxicity: Reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle. If Grade 3 or greater toxicity recurs, reduce dose to 25 mg/m2 on Days 1 and 2 of each cycle. Dose re-escalation in subsequent cycles may be considered per physician discretion. Clinically Significant Grade 3 or Greater Non-Hematologic Toxicity: Reduce dose to 50 mg/m2 on Days 1 and 2 of each cycle. Dose re-escalation in subsequent cycles may be considered per physician discretion. NHL: Grade 4 Hematologic Toxicity or Grade 3 or Greater Non-Hematologic Toxicity: Reduce dose to 90 mg/m2 on Days 1 and 2 of each cycle. If Grade 4 hematologic or Grade 3 or greater non-hematologic toxicity recurs, reduce dose to 60 mg/m2 on Days 1 and 2 of each cycle. Side Effects The Most Common nausea vomiting diarrhea heartburn constipation stomach pain or swelling sores or white patches in the mouth dry mouth bad taste in the mouth or difficulty tasting food loss of appetite weight loss headache anxiety depression difficulty falling asleep or staying asleep back, bone, joint, arm or leg pain dry skin sweating night sweats More common pain in the place where the medication was injected hives rash itching blistering or peeling skin difficulty breathing or swallowing swelling of the eyes, face, lips, tongue, arms, hands, feet, ankles, or lower legs shortness of breath chest pain fast heartbeat excessive tiredness or weakness pale skin fever, chills, cough, or other signs of infection nausea; vomiting; unusual bleeding or bruising; yellowing of the skin or eyes, dark urine, or light colored stool; tenderness on the right upper side of the stomach Rare dehydration (thirst, dizziness, dry mouth, less urine output) difficulty breathing fever (over 38°C, or as instructed by your physician or clinic) lumps or discoloured patches on the skin signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don't stop bleeding) signs of increased uric acid in the body (gout; e.g., joint pain, swelling and warmth of joints) signs of heart problems (e.g., fast, irregular heartbeat or pulse, chest pain, sudden weight gain, difficulty breathing, leg swelling) signs of kidney problems (e.g., increased urination at night, decreased urine production, blood in the urine, change of urine colour) signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools) skin growths or changes to existing skin growths or sores skin rash symptoms of extravasation (leakage of drug from the veins; redness, pain, swelling or infection at the site of infusion) symptoms of an infection such as fever, chills, or painful and difficult urination symptoms of a new cancer (e.g., weight loss, fatigue, night sweats, loss of appetite, coughing up blood, persistent cough, fever, frequent infections, bone pain) symptoms of irregular heartbeat (e.g., chest pain, dizziness, rapid, pounding heartbeat, shortness of breath) symptoms of low potassium levels in the blood (e.g., weakness, fatigue, muscle cramps, irregular heartbeat) symptoms of a lung infection (e.g., shortness of breath, cough, chest pain) symptoms of scarring of the lung (e.g., shortness of breath, fatigue, fever, infection) symptoms of severely increased blood pressure (e.g., chest pain, blurred vision, dizziness, excessive tiredness, headache, stronger or faster heart beat) Seek immediate medical attention if any of the following occur: signs of bleeding in the stomach (e.g., bloody, black, or tarry stools, spitting up of blood, vomiting blood or material that looks like coffee grounds) signs of a heart attack (e.g., chest pain or pressure, pain extending through shoulder and arm, nausea and vomiting, sweating) symptoms of a serious allergic reaction, such as hives, difficulty breathing, or swelling of the eyelids, throat, and mouth signs of a severe skin reaction such as blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort symptoms of progressive multifocal leukoencephalopathy (PML) (e.g., memory loss, trouble thinking, difficulty walking, loss of sight) symptoms of tumor lysis syndrome (e.g., producing less urine, cloudy urine, kidney problems, muscle spasms, nausea, shortness of breath) Bendamustine therapy is associated with minor transient serum enzyme elevations during treatment and to rare instances of clinically apparent liver injury, with jaundice generally arising as a part of a generalized hypersensitivity syndrome. Bendamustine also has potent immunosuppressive activity and can cause reactivation of chronic hepatitis B that can be severe and even fatal. Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Bendamustine can be increased when it is combined with Abametapir. Abatacept The metabolism of Bendamustine can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Bendamustine. Abiraterone The serum concentration of Bendamustine can be increased when it is combined with Abiraterone. Abrocitinib The serum concentration of Bendamustine can be increased when it is combined with Abrocitinib. Acenocoumarol The metabolism of Bendamustine can be decreased when combined with Acenocoumarol. Acetaminophen The metabolism of Bendamustine can be decreased when combined with Acetaminophen. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bendamustine. Acyclovir The metabolism of Bendamustine can be decreased when combined with Acyclovir. Adalimumab The metabolism of Bendamustine can be increased when combined with Adalimumab. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bendamustine. Afatinib The serum concentration of Bendamustine can be increased when it is combined with Afatinib. Agomelatine The metabolism of Bendamustine can be decreased when combined with Agomelatine. Albendazole The serum concentration of Bendamustine can be increased when it is combined with Albendazole. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendamustine. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Bendamustine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bendamustine. Allogeneic processed The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bendamustine. Allopurinol The risk or severity of rash, hypersensitivity reaction, Stevens-Johnson syndrome, and Cutaneous drug reaction can be increased when Allopurinol is combined with Bendamustine. Alosetron The metabolism of Bendamustine can be decreased when combined with Alosetron. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Bendamustine. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Bendamustine. Ambrisentan The serum concentration of Bendamustine can be increased when it is combined with Ambrisentan. Aminophenazone The metabolism of Bendamustine can be decreased when combined with Aminophenazone. Aminophylline The metabolism of Bendamustine can be decreased when combined with Aminophylline. Amiodarone The serum concentration of Bendamustine can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Bendamustine can be decreased when combined with Amitriptyline. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Bendamustine. Anagrelide The metabolism of Bendamustine can be decreased when combined with Anagrelide. Anakinra The metabolism of Bendamustine can be increased when combined with Anakinra. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Bendamustine. Anifrolumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Bendamustine. Anthrax immune globulin The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bendamustine. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Bendamustine. Antilymphocyte The risk or severity of adverse effects can be increased when Bendamustine is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Bendamustine can be decreased when combined with Antipyrine. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bendamustine. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bendamustine. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bendamustine. Apalutamide The serum concentration of Bendamustine can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Bendamustine can be increased when it is combined with Apixaban. Apremilast The metabolism of Bendamustine can be increased when combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Bendamustine. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Bendamustine. Armodafinil The metabolism of Bendamustine can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Bendamustine can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Articaine. Asciminib The serum concentration of Bendamustine can be increased when it is combined with Asciminib. Asenapine The metabolism of Bendamustine can be decreased when combined with Asenapine. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bendamustine. Asunaprevir The serum concentration of Bendamustine can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Bendamustine can be decreased when combined with Atazanavir. Avanafil The serum concentration of Bendamustine can be increased when it is combined with Avanafil. Avatrombopag The serum concentration of Bendamustine can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Bendamustine can be decreased when combined with Axitinib. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Bendamustine. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Bendamustine. Azelastine The metabolism of Bendamustine can be decreased when combined with Azelastine. Bacillus calmette-guerin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bendamustine. Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bendamustine. Bacillus calmette-guerin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bendamustine. Baricitinib The risk or severity of adverse effects can be increased when Bendamustine is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Bendamustine. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Bendamustine. Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Bendamustine. Belantamab mafodotin The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Bendamustine. Belimumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Bendamustine. Belumosudil The serum concentration of Bendamustine can be increased when it is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bendamustine. Benzocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bendamustine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Benzyl alcohol. Berotralstat The serum concentration of Bendamustine can be increased when it is combined with Berotralstat. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Bendamustine. Betaxolol The metabolism of Bendamustine can be decreased when combined with Betaxolol. Betrixaban The serum concentration of Bendamustine can be increased when it is combined with Betrixaban. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Bendamustine. Bimekizumab The metabolism of Bendamustine can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Bendamustine. Bisoprolol The serum concentration of Bendamustine can be increased when it is combined with Bisoprolol. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Bendamustine. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Bendamustine. Blinatumomab The risk or severity of adverse effects can be increased when Bendamustine is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Bendamustine. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Bendamustine. Bosutinib The risk or severity of adverse effects can be increased when Bosutinib is combined with Bendamustine. Brentuximab vedotin The risk or severity of adverse effects can be increased when Bendamustine is combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Brodalumab. Bromazepam The metabolism of Bendamustine can be decreased when combined with Bromazepam. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Bendamustine. Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Bendamustine. Bupivacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Bupivacaine. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Bendamustine. Butacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Bendamustine is combined with Cabazitaxel. Canagliflozin The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Bendamustine can be increased when combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Bendamustine. Cannabidiol The metabolism of Bendamustine can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Bendamustine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Bendamustine. Capmatinib The serum concentration of Bendamustine can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Capsaicin. Carbamazepine The serum concentration of Bendamustine can be increased when it is combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Bendamustine. Carfilzomib The serum concentration of Bendamustine can be increased when it is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Bendamustine. Carvedilol The serum concentration of Bendamustine can be increased when it is combined with Carvedilol. Ceritinib The serum concentration of Bendamustine can be increased when it is combined with Ceritinib. Certolizumab pegol The metabolism of Bendamustine can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bendamustine. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Bendamustine. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Chloroprocaine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bendamustine. Chlorpromazine The metabolism of Bendamustine can be decreased when combined with Chlorpromazine. Chlorzoxazone The metabolism of Bendamustine can be decreased when combined with Chlorzoxazone. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Bendamustine. Cilostazol The metabolism of Bendamustine can be decreased when combined with Cilostazol. Cimetidine The metabolism of Bendamustine can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Bendamustine can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Cinchocaine. Cinnarizine The metabolism of Bendamustine can be decreased when combined with Cinnarizine. Cinoxacin The metabolism of Bendamustine can be decreased when combined with Cinoxacin. Ciprofloxacin The serum concentration of Bendamustine can be increased when it is combined with Ciprofloxacin. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Bendamustine. Citalopram The metabolism of Bendamustine can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Bendamustine. Clarithromycin The serum concentration of Bendamustine can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Bendamustine can be increased when it is combined with Clobazam. Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Bendamustine. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Bendamustine. Clofazimine The serum concentration of Bendamustine can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Bendamustine can be increased when it is combined with Clomifene. Clomipramine The metabolism of Bendamustine can be decreased when combined with Clomipramine. Clonidine The metabolism of Bendamustine can be decreased when combined with Clonidine. Clopidogrel The metabolism of Bendamustine can be decreased when combined with Clopidogrel. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bendamustine. Clozapine The risk or severity of neutropenia can be increased when Bendamustine is combined with Clozapine. Cobicistat The serum concentration of Bendamustine can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Bendamustine can be increased when it is combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Cocaine. Colchicine The serum concentration of Bendamustine can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Bendamustine can be increased when it is combined with Conivaptan. Conjugated estrogens The metabolism of Bendamustine can be decreased when combined with Conjugated estrogens. Copanlisib The serum concentration of Bendamustine can be increased when it is combined with Copanlisib. Corticotropin The risk or severity of adverse effects can be increased when Corticotropin is combined with Bendamustine. Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Bendamustine. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bendamustine. Crizotinib The serum concentration of Bendamustine can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Bendamustine can be increased when it is combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bendamustine. Cyclobenzaprine The metabolism of Bendamustine can be decreased when combined with Cyclobenzaprine. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bendamustine. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bendamustine. Cyclosporine Bendamustine may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bendamustine. Cyproterone acetate The metabolism of Bendamustine can be increased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Bendamustine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Bendamustine. Dabigatran etexilate The serum concentration of Bendamustine can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Bendamustine can be increased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bendamustine. Daclatasvir The serum concentration of Bendamustine can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Bendamustine can be increased when it is combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bendamustine. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Bendamustine. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Bendamustine. Dapagliflozin The metabolism of Bendamustine can be decreased when combined with Dapagliflozin. Daptomycin The serum concentration of Bendamustine can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bendamustine. Darolutamide The serum concentration of Bendamustine can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Bendamustine can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Bendamustine can be increased when it is combined with Dasabuvir. Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Bendamustine. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Bendamustine. Deferasirox The serum concentration of Bendamustine can be increased when it is combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Bendamustine. Deflazacort The risk or severity of adverse effects can be increased when Bendamustine is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Bendamustine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Bendamustine. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Bendamustine. Deucravacitinib The risk or severity of adverse effects can be increased when Bendamustine is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Bendamustine. Dexamethasone acetate The serum concentration of Bendamustine can be decreased when it is combined with Dexamethasone acetate. Dexfenfluramine The metabolism of Bendamustine can be decreased when combined with Dexfenfluramine. Dexmedetomidine The metabolism of Bendamustine can be decreased when combined with Dexmedetomidine. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bendamustine. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Bendamustine. Diacerein The metabolism of Bendamustine can be decreased when combined with Diacerein. Diclofenac The metabolism of Bendamustine can be decreased when combined with Diclofenac. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Bendamustine. Difluocortolone The risk or severity of adverse effects can be increased when Bendamustine is combined with Difluocortolone. Digitoxin The serum concentration of Bendamustine can be increased when it is combined with Digitoxin. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Bendamustine. Edoxaban The serum concentration of Bendamustine can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Bendamustine. Efavirenz The metabolism of Bendamustine can be decreased when combined with Efavirenz. Elagolix The serum concentration of Bendamustine can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Bendamustine can be increased when it is combined with Elbasvir. Eliglustat The serum concentration of Bendamustine can be increased when it is combined with Eliglustat. Eltrombopag The metabolism of Bendamustine can be decreased when combined with Eltrombopag. Emapalumab The metabolism of Bendamustine can be increased when combined with Emapalumab. Enasidenib The serum concentration of Bendamustine can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Bendamustine can be increased when it is combined with Enfortumab vedotin. Enoxacin The serum concentration of Bendamustine can be increased when it is combined with Enoxacin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Bendamustine. Entecavir The metabolism of Bendamustine can be decreased when combined with Entecavir. Entrectinib The serum concentration of Bendamustine can be increased when it is combined with Entrectinib. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Bendamustine. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Bendamustine. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Bendamustine. Erdafitinib The serum concentration of Bendamustine can be increased when it is combined with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Bendamustine is combined with Eribulin. Erlotinib The metabolism of Bendamustine can be decreased when combined with Erlotinib. Ertugliflozin The serum concentration of Bendamustine can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Bendamustine can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bendamustine. Estradiol The metabolism of Bendamustine can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Bendamustine can be decreased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Bendamustine can be decreased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Bendamustine. Estradiol dienanthate The metabolism of Bendamustine can be decreased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Bendamustine can be decreased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Bendamustine. Estrone sulfate The metabolism of Bendamustine can be decreased when combined with Estrone sulfate. Etanercept The metabolism of Bendamustine can be increased when combined with Etanercept. Ethambutol The metabolism of Bendamustine can be decreased when combined with Ethambutol. Ethanol The metabolism of Bendamustine can be decreased when combined with Ethanol. Ethinylestradiol The metabolism of Bendamustine can be decreased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Bendamustine. Etoricoxib The metabolism of Bendamustine can be decreased when combined with Etoricoxib. Everolimus The serum concentration of Bendamustine can be increased when it is combined with Everolimus. Famotidine The metabolism of Bendamustine can be decreased when combined with Famotidine. Favipiravir The serum concentration of Bendamustine can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Bendamustine can be increased when it is combined with Fedratinib. Fenfluramine The metabolism of Bendamustine can be decreased when combined with Fenfluramine. Fexinidazole The metabolism of Bendamustine can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Bendamustine can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Bendamustine can be increased when it is combined with Filgotinib. Fingolimod Bendamustine may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Bendamustine can be decreased when combined with Flecainide. Flibanserin The serum concentration of Bendamustine can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Bendamustine. Fluconazole The serum concentration of Bendamustine can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Bendamustine. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Bendamustine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bendamustine. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Bendamustine. Flunarizine The metabolism of Bendamustine can be decreased when combined with Flunarizine. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Bendamustine. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Bendamustine. Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Bendamustine. Fluocortolone The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Bendamustine. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bendamustine. Fluoxetine The metabolism of Bendamustine can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bendamustine. Fluprednisolone The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluprednisolone. Flutamide The metabolism of Bendamustine can be decreased when combined with Flutamide. Fluticasone The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Bendamustine. Fluvoxamine The serum concentration of Bendamustine can be increased when it is combined with Fluvoxamine. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Bendamustine. Fosphenytoin The metabolism of Bendamustine can be increased when combined with Fosphenytoin. Fostemsavir The serum concentration of Bendamustine can be increased when it is combined with Fostemsavir. Frovatriptan The metabolism of Bendamustine can be decreased when combined with Frovatriptan. Futibatinib The serum concentration of Bendamustine can be increased when it is combined with Futibatinib. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Bendamustine. Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Bendamustine. Isavuconazole The serum concentration of Bendamustine can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Bendamustine can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Bendamustine can be decreased when combined with Isoniazid. Istradefylline The serum concentration of Bendamustine can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Bendamustine can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Bendamustine can be increased when it is combined with Ivacaftor. Ixabepilone The serum concentration of Bendamustine can be increased when it is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Ixekizumab. Janssen COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Bendamustine. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bendamustine. Ketoconazole The serum concentration of Bendamustine can be increased when it is combined with Ketoconazole. Lapatinib The serum concentration of Bendamustine can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Bendamustine can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Bendamustine can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Bendamustine can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Bendamustine can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Bendamustine is combined with Leflunomide. Lemborexant The serum concentration of Bendamustine can be increased when it is combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bendamustine. Lenvatinib The serum concentration of Bendamustine can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Levobupivacaine. Levoketoconazole The serum concentration of Bendamustine can be increased when it is combined with Levoketoconazole. Levothyroxine The serum concentration of Bendamustine can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Lidocaine. Linagliptin The serum concentration of Bendamustine can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Bendamustine. Loperamide The serum concentration of Bendamustine can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Bendamustine can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Bendamustine can be decreased when combined with Lorcaserin. Lorlatinib The serum concentration of Bendamustine can be decreased when it is combined with Lorlatinib. Loxapine The serum concentration of Bendamustine can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Bendamustine can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Bendamustine can be increased when it is combined with Lusutrombopag. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Bendamustine. Mannitol The serum concentration of Bendamustine can be increased when it is combined with Mannitol. Maprotiline The metabolism of Bendamustine can be decreased when combined with Maprotiline. Maribavir The serum concentration of Bendamustine can be increased when it is combined with Maribavir. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Bendamustine. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Bendamustine. Mefenamic acid The metabolism of Bendamustine can be decreased when combined with Mefenamic acid. Mefloquine The serum concentration of Bendamustine can be increased when it is combined with Mefloquine. Melatonin The metabolism of Bendamustine can be decreased when combined with Melatonin. Meloxicam The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Bendamustine. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Bendamustine. Mephenytoin The metabolism of Bendamustine can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bendamustine. Meprednisone The risk or severity of adverse effects can be increased when Bendamustine is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bendamustine. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Bendamustine. Methotrexate The excretion of Methotrexate can be decreased when combined with Bendamustine. Methoxsalen The metabolism of Bendamustine can be decreased when combined with Methoxsalen. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bendamustine. Methylene blue The serum concentration of Bendamustine can be increased when it is combined with Methylene blue. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bendamustine. Metoclopramide The metabolism of Bendamustine can be decreased when combined with Metoclopramide. Mexiletine The metabolism of Bendamustine can be decreased when combined with Mexiletine. Mianserin The metabolism of Bendamustine can be decreased when combined with Mianserin. Mifepristone The serum concentration of Bendamustine can be decreased when it is combined with Mifepristone. Mirabegron The serum concentration of Bendamustine can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Bendamustine can be decreased when combined with Mirtazapine. Mitapivat The serum concentration of Bendamustine can be increased when it is combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Bendamustine. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bendamustine. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bendamustine. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bendamustine. Mometasone furoate The risk or severity of adverse effects can be increased when Bendamustine is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Bendamustine is combined with Monomethyl fumarate. Morphine The serum concentration of Bendamustine can be increased when it is combined with Morphine. Mosunetuzumab The metabolism of Bendamustine can be decreased when combined with Mosunetuzumab. Moxifloxacin The metabolism of Bendamustine can be decreased when combined with Moxifloxacin. Mumps virus strain B The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bendamustine. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bendamustine. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bendamustine. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bendamustine. Nabumetone The metabolism of Bendamustine can be decreased when combined with Nabumetone. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Bendamustine. Nafcillin The metabolism of Bendamustine can be increased when combined with Nafcillin. Nalidixic acid The metabolism of Bendamustine can be decreased when combined with Nalidixic acid. Naproxen The metabolism of Bendamustine can be decreased when combined with Naproxen. Natalizumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Natalizumab. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Bendamustine. Neratinib The serum concentration of Bendamustine can be increased when it is combined with Neratinib. Netupitant The serum concentration of Bendamustine can be increased when it is combined with Netupitant. Nevirapine The metabolism of Bendamustine can be decreased when combined with Nevirapine. Niclosamide The metabolism of Bendamustine can be decreased when combined with Niclosamide. Nifedipine The metabolism of Bendamustine can be decreased when combined with Nifedipine. Nilotinib The serum concentration of Bendamustine can be increased when it is combined with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Bendamustine. Nintedanib The serum concentration of Bendamustine can be increased when it is combined with Nintedanib. Norfloxacin The metabolism of Bendamustine can be decreased when combined with Norfloxacin. Norgestimate The serum concentration of Bendamustine can be increased when it is combined with Norgestimate. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bendamustine. Obeticholic acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Bendamustine. Obinutuzumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Bendamustine. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bendamustine. Olanzapine The metabolism of Bendamustine can be decreased when combined with Olanzapine. Olaparib The risk or severity of adverse effects can be increased when Bendamustine is combined with Olaparib. Omadacycline The serum concentration of Bendamustine can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Bendamustine can be increased when it is combined with Ombitasvir. Omeprazole The metabolism of Bendamustine can be increased when combined with Omeprazole. Ondansetron The metabolism of Bendamustine can be decreased when combined with Ondansetron. Orphenadrine The metabolism of Bendamustine can be decreased when combined with Orphenadrine. Osilodrostat The serum concentration of Bendamustine can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Bendamustine can be decreased when it is combined with Osimertinib. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bendamustine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Oxetacaine. Oxtriphylline The metabolism of Bendamustine can be decreased when combined with Oxtriphylline. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Oxybuprocaine. Ozanimod The risk or severity of adverse effects can be increased when Bendamustine is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine. Pacritinib The serum concentration of Bendamustine can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Bendamustine can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Bendamustine. Paliperidone The serum concentration of Bendamustine can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Bendamustine. Paritaprevir The serum concentration of Bendamustine can be increased when it is combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Bendamustine. Paroxetine The metabolism of Bendamustine can be decreased when combined with Paroxetine. Pazopanib The risk or severity of adverse effects can be increased when Pazopanib is combined with Bendamustine. Pefloxacin The metabolism of Bendamustine can be decreased when combined with Pefloxacin. Loperamide The serum concentration of Bendamustine can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Bendamustine can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Bendamustine can be decreased when combined with Lorcaserin. Lorlatinib The serum concentration of Bendamustine can be decreased when it is combined with Lorlatinib. Loxapine The serum concentration of Bendamustine can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Bendamustine can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Bendamustine can be increased when it is combined with Lusutrombopag. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Bendamustine. Mannitol The serum concentration of Bendamustine can be increased when it is combined with Mannitol. Maprotiline The metabolism of Bendamustine can be decreased when combined with Maprotiline. Maribavir The serum concentration of Bendamustine can be increased when it is combined with Maribavir. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Bendamustine. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Bendamustine. Mefenamic acid The metabolism of Bendamustine can be decreased when combined with Mefenamic acid. Mefloquine The serum concentration of Bendamustine can be increased when it is combined with Mefloquine. Melatonin The metabolism of Bendamustine can be decreased when combined with Melatonin. Meloxicam The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Bendamustine. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Bendamustine. Mephenytoin The metabolism of Bendamustine can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bendamustine. Meprednisone The risk or severity of adverse effects can be increased when Bendamustine is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bendamustine. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Bendamustine. Methotrexate The excretion of Methotrexate can be decreased when combined with Bendamustine. Methoxsalen The metabolism of Bendamustine can be decreased when combined with Methoxsalen. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bendamustine. Methylene blue The serum concentration of Bendamustine can be increased when it is combined with Methylene blue. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bendamustine. Metoclopramide The metabolism of Bendamustine can be decreased when combined with Metoclopramide. Mexiletine The metabolism of Bendamustine can be decreased when combined with Mexiletine. Mianserin The metabolism of Bendamustine can be decreased when combined with Mianserin. Mifepristone The serum concentration of Bendamustine can be decreased when it is combined with Mifepristone. Mirabegron The serum concentration of Bendamustine can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Bendamustine can be decreased when combined with Mirtazapine. Mitapivat The serum concentration of Bendamustine can be increased when it is combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Bendamustine. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bendamustine. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bendamustine. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bendamustine. Mometasone furoate The risk or severity of adverse effects can be increased when Bendamustine is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Bendamustine is combined with Monomethyl fumarate. Morphine The serum concentration of Bendamustine can be increased when it is combined with Morphine. Mosunetuzumab The metabolism of Bendamustine can be decreased when combined with Mosunetuzumab. Moxifloxacin The metabolism of Bendamustine can be decreased when combined with Moxifloxacin. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bendamustine. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bendamustine. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bendamustine. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bendamustine. Nabumetone The metabolism of Bendamustine can be decreased when combined with Nabumetone. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Bendamustine. Nafcillin The metabolism of Bendamustine can be increased when combined with Nafcillin. Nalidixic acid The metabolism of Bendamustine can be decreased when combined with Nalidixic acid. Naproxen The metabolism of Bendamustine can be decreased when combined with Naproxen. Natalizumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Natalizumab. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Bendamustine. Neratinib The serum concentration of Bendamustine can be increased when it is combined with Neratinib. Netupitant The serum concentration of Bendamustine can be increased when it is combined with Netupitant. Nevirapine The metabolism of Bendamustine can be decreased when combined with Nevirapine. Niclosamide The metabolism of Bendamustine can be decreased when combined with Niclosamide. Nifedipine The metabolism of Bendamustine can be decreased when combined with Nifedipine. Nilotinib The serum concentration of Bendamustine can be increased when it is combined with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Bendamustine. Nintedanib The serum concentration of Bendamustine can be increased when it is combined with Nintedanib. Norfloxacin The metabolism of Bendamustine can be decreased when combined with Norfloxacin. Norgestimate The serum concentration of Bendamustine can be increased when it is combined with Norgestimate. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bendamustine. Obeticholic acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Bendamustine. Obinutuzumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Bendamustine. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Bendamustine. Olanzapine The metabolism of Bendamustine can be decreased when combined with Olanzapine. Olaparib The risk or severity of adverse effects can be increased when Bendamustine is combined with Olaparib. Omadacycline The serum concentration of Bendamustine can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Bendamustine can be increased when it is combined with Ombitasvir. Omeprazole The metabolism of Bendamustine can be increased when combined with Omeprazole. Ondansetron The metabolism of Bendamustine can be decreased when combined with Ondansetron. Orphenadrine The metabolism of Bendamustine can be decreased when combined with Orphenadrine. Osilodrostat The serum concentration of Bendamustine can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Bendamustine can be decreased when it is combined with Osimertinib. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bendamustine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Oxetacaine. Oxtriphylline The metabolism of Bendamustine can be decreased when combined with Oxtriphylline. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Oxybuprocaine. Ozanimod The risk or severity of adverse effects can be increased when Bendamustine is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine. Pacritinib The serum concentration of Bendamustine can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Bendamustine can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Bendamustine. Paliperidone The serum concentration of Bendamustine can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Bendamustine. Paritaprevir The serum concentration of Bendamustine can be increased when it is combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Bendamustine. Paroxetine The metabolism of Bendamustine can be decreased when combined with Paroxetine. Pazopanib The risk or severity of adverse effects can be increased when Pazopanib is combined with Bendamustine. Pefloxacin The metabolism of Bendamustine can be decreased when combined with Pefloxacin. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Bendamustine. Phenol The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Bendamustine. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bendamustine. Phenylephrine The metabolism of Bendamustine can be increased when combined with Phenylephrine. Pibrentasvir The serum concentration of Bendamustine can be increased when it is combined with Pibrentasvir. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bendamustine. Pimozide The metabolism of Bendamustine can be decreased when combined with Pimozide. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Bendamustine. Pitolisant The metabolism of Bendamustine can be increased when combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bendamustine. Pomalidomide The risk or severity of adverse effects can be increased when Bendamustine is combined with Pomalidomide. Ponatinib The serum concentration of Bendamustine can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Bendamustine is combined with Ponesimod. Posaconazole The serum concentration of Bendamustine can be increased when it is combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Bendamustine is combined with Pralatrexate. Pralsetinib The serum concentration of Bendamustine can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Bendamustine. Pravastatin The serum concentration of Bendamustine can be increased when it is combined with Pravastatin. Praziquantel The metabolism of Bendamustine can be decreased when combined with Praziquantel. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Bendamustine. Prednisolone phosphate The serum concentration of Bendamustine can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Bendamustine. Prilocaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Prilocaine. Primaquine The metabolism of Bendamustine can be increased when combined with Primaquine. Primidone The serum concentration of Bendamustine can be increased when it is combined with Primidone. Procaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Bendamustine. Promazine The metabolism of Bendamustine can be decreased when combined with Promazine. Propafenone The serum concentration of Bendamustine can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Propoxycaine. Propranolol The metabolism of Bendamustine can be decreased when combined with Propranolol. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bendamustine. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Bendamustine. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Bendamustine. Quinidine The serum concentration of Bendamustine can be increased when it is combined with Quinidine. Quinine The serum concentration of Bendamustine can be increased when it is combined with Quinine. Rabies immune globulin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bendamustine. Rabies virus antigen The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bendamustine. Rabies antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bendamustine. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bendamustine. Ramelteon The metabolism of Bendamustine can be decreased when combined with Ramelteon. Ranitidine The metabolism of Bendamustine can be decreased when combined with Ranitidine. Ranolazine The serum concentration of Bendamustine can be increased when it is combined with Ranolazine. Rasagiline The metabolism of Bendamustine can be decreased when combined with Rasagiline. Ravulizumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Ravulizumab. Regorafenib The serum concentration of Bendamustine can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Bendamustine can be increased when it is combined with Relugolix. Reserpine The serum concentration of Bendamustine can be increased when it is combined with Reserpine. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Bendamustine. Revefenacin The serum concentration of Bendamustine can be increased when it is combined with Revefenacin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Bendamustine. Rifampicin The serum concentration of Bendamustine can be increased when it is combined with Rifampicin. Rifamycin The serum concentration of Bendamustine can be increased when it is combined with Rifamycin. Rilonacept The metabolism of Bendamustine can be increased when combined with Rilonacept. Riluzole The metabolism of Bendamustine can be decreased when combined with Riluzole. Rimegepant The serum concentration of Bendamustine can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Bendamustine can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Bendamustine can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Risankizumab. Ritonavir The serum concentration of Bendamustine can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Bendamustine. Rivaroxaban The serum concentration of Bendamustine can be increased when it is combined with Rivaroxaban. Rofecoxib The serum concentration of Bendamustine can be increased when it is combined with Rofecoxib. Roflumilast Roflumilast may increase the immunosuppressive activities of Bendamustine. Rolapitant The serum concentration of Bendamustine can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Bendamustine can be increased when it is combined with Romidepsin. Ropeginterferon The risk or severity of adverse effects can be increased when Bendamustine is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Ropivacaine. Rosoxacin The metabolism of Bendamustine can be decreased when combined with Rosoxacin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bendamustine. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bendamustine. Rucaparib The metabolism of Bendamustine can be decreased when combined with Rucaparib. Ruxolitinib The risk or severity of adverse effects can be increased when Bendamustine is combined with Ruxolitinib. Sapropterin The serum concentration of Bendamustine can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Bendamustine can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Bendamustine can be increased when it is combined with Sarecycline. Sarilumab The risk or severity of adverse effects can be increased when Bendamustine is combined with Sarilumab. Satralizumab The serum concentration of Bendamustine can be decreased when it is combined with Satralizumab. Secukinumab The metabolism of Bendamustine can be increased when combined with Secukinumab. Selegiline The metabolism of Bendamustine can be decreased when combined with Selegiline. Selexipag The serum concentration of Bendamustine can be increased when it is combined with Selexipag. Selumetinib The metabolism of Selumetinib can be decreased when combined with Bendamustine. Sildenafil The serum concentration of Bendamustine can be increased when it is combined with Sildenafil. Siltuximab The metabolism of Bendamustine can be increased when combined with Siltuximab. Simeprevir The serum concentration of Bendamustine can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Bendamustine can be increased when it is combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Bendamustine is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bendamustine. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Bendamustine. Sitagliptin The serum concentration of Bendamustine can be increased when it is combined with Sitagliptin. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bendamustine. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Bendamustine. Sofosbuvir The serum concentration of Bendamustine can be increased when it is combined with Sofosbuvir. Somapacitan The metabolism of Bendamustine can be increased when combined with Somapacitan. Somatotropin The metabolism of Bendamustine can be increased when combined with Somatotropin. Somatrem The metabolism of Bendamustine can be increased when combined with Somatrem. Somatrogon The metabolism of Bendamustine can be increased when combined with Somatrogon. Sorafenib The serum concentration of Bendamustine can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Bendamustine can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Bendamustine can be increased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Bendamustine is combined with Spesolimab. St. John's Wort The serum concentration of Bendamustine can be decreased when it is combined with St. John's Wort. Stiripentol The metabolism of Bendamustine can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Bendamustine. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Bendamustine. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bendamustine. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bendamustine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bendamustine. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Bendamustine. Sunitinib The risk or severity of adverse effects can be increased when Sunitinib is combined with Bendamustine. Suvorexant The serum concentration of Bendamustine can be increased when it is combined with Suvorexant. Tacrine The metabolism of Bendamustine can be decreased when combined with Tacrine. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Bendamustine. Talazoparib The serum concentration of Bendamustine can be increased when it is combined with Talazoparib. Tamoxifen The serum concentration of Bendamustine can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Bendamustine. Tazemetostat The serum concentration of Bendamustine can be increased when it is combined with Tazemetostat. Technetium The serum concentration of Bendamustine can be increased when it is combined with Technetium Tc-99m sestamibi. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Bendamustine is combined with Tedizolid phosphate. Tegafur The metabolism of Tegafur can be decreased when combined with Bendamustine. Tegaserod The metabolism of Bendamustine can be decreased when combined with Tegaserod. Telaprevir The serum concentration of Bendamustine can be increased when it is combined with Telaprevir. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Bendamustine. Temsirolimus The serum concentration of Bendamustine can be increased when it is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Bendamustine. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Bendamustine. Tenofovir disoproxil The serum concentration of Bendamustine can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Bendamustine can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bendamustine. Terbinafine The metabolism of Bendamustine can be decreased when combined with Terbinafine. Teriflunomide The serum concentration of Bendamustine can be decreased when it is combined with Teriflunomide. Tetracaine The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Tetracaine. Tezacaftor The serum concentration of Bendamustine can be increased when it is combined with Tezacaftor. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Bendamustine. Theophylline The metabolism of Bendamustine can be decreased when combined with Theophylline. Thiabendazole The metabolism of Bendamustine can be decreased when combined with Thiabendazole. Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Bendamustine. Thiothixene The metabolism of Bendamustine can be decreased when combined with Thiothixene. Ticagrelor The serum concentration of Bendamustine can be increased when it is combined with Ticagrelor. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Bendamustine. Ticlopidine The metabolism of Bendamustine can be decreased when combined with Ticlopidine. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Bendamustine. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Bendamustine. Tipranavir The serum concentration of Bendamustine can be decreased when it is combined with Tipranavir. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Bendamustine. Tivozanib The serum concentration of Bendamustine can be increased when it is combined with Tivozanib. Tixocortol The risk or severity of adverse effects can be increased when Bendamustine is combined with Tixocortol. Tizanidine The metabolism of Bendamustine can be decreased when combined with Tizanidine. Tocainide The metabolism of Bendamustine can be decreased when combined with Tocainide. Tocilizumab The metabolism of Bendamustine can be increased when combined with Tocilizumab. Tofacitinib Bendamustine may increase the immunosuppressive activities of Tofacitinib. Tolvaptan The serum concentration of Bendamustine can be increased when it is combined with Tolvaptan. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Bendamustine. Toremifene The serum concentration of Bendamustine can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Bendamustine. Trabectedin The risk or severity of adverse effects can be increased when Trabectedin is combined with Bendamustine. Trastuzumab Trastuzumab may increase the neutropenic activities of Bendamustine. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bendamustine. Trazodone The serum concentration of Bendamustine can be decreased when it is combined with Trazodone. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Bendamustine. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Bendamustine. Triamterene The metabolism of Bendamustine can be decreased when combined with Triamterene. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Bendamustine. Triclabendazole The metabolism of Bendamustine can be decreased when combined with Triclabendazole. Trifluoperazine The metabolism of Bendamustine can be decreased when combined with Trifluoperazine. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Bendamustine. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Bendamustine. Trilaciclib The metabolism of Bendamustine can be increased when combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Bendamustine. Trovafloxacin The metabolism of Bendamustine can be decreased when combined with Trovafloxacin. Tucatinib The serum concentration of Bendamustine can be increased when it is combined with Tucatinib. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bendamustine. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bendamustine. Typhoid  vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bendamustine. Ubrogepant The serum concentration of Bendamustine can be increased when it is combined with Ubrogepant. Umbralisib The serum concentration of Bendamustine can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Bendamustine can be increased when it is combined with Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Bendamustine is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Bendamustine. Valproic acid The metabolism of Bendamustine can be decreased when combined with Valproic acid. Vandetanib The serum concentration of Bendamustine can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Bendamustine can be increased when it is combined with Vardenafil. Pregnancy and Lactation Pregnancy category D Pregnancy There is a possibility of birth defects if either the man or woman is taking bendamustine at the time of conception, or if it is taken during pregnancy. Use effective birth control starting 2 weeks before receiving this medication and for at least 4 weeks after receiving your last dose. If you become pregnant while taking this medication, contact your doctor immediately. Lactation No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as bendamustine.[1] Based on the half-life of the drug and its metabolites, the drug should be eliminated from the milk by 24 to 48 hours after the last dose. The manufacturer recommends that breastfeeding be discontinued during bendamustine therapy and for at least 1 week after the last dose. How should this medicine be used?

For chronic lymphocytic leukemia, the usual adult dose is 100 mg per square metre of body surface area. It is given intravenously (directly into a vein) over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. For non-Hodgkin's lymphoma, the usual dose is 120 mg per square metre of body surface area. It is given intravenously (directly into a vein) over 60 minutes of Days 1 and 2 of a 21-day cycle, up to 8 cycles.…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)